Sun Pharmaceutical Industries today posted consolidated net profit rose 12.2% to Rs 442.75 crore for the quarter ended March 31, 2011, while its consolidated net profit for the financial year ended March 31, 2011, stood at Rs 1,816.06 crore.
The company, which reported consolidated net sales of Rs 5,721 crore for the year ended March 31, 2011, said it expected a growth of 28-30% in the current fiscal.
"We expect the revenues to grow from 28-30% in FY12 from the revenues of FY11 based on growth in all markets," Shanghvi said.
The company posted consolidated net sales of Rs 5,721 crore for the year ended March 31, 2011, a growth of 43% from FY10.
The company said it planned to invest Rs 450 crore for capacity expansion and upgradation of existing plants, including its Taro facilities, in the current fiscal.
"We will be spending about Rs 450 crore in capex this year for both capacity expansion and upgradation of formulation factories and bulk drug factories. It also includes investments planned for Taro facilities," Sun Pharma Chairman and Managing Director Dilip Shanghvi said.
Israel-based Taro pharmaceutical industries became Sun Pharma's subsidiary on September 20, 2010.
Besides, the company is planning to expand its operations in both the US and emerging markets, it said without giving further details.
Shares of Sun Pharma were trading at Rs 459.25 on the Bombay Stock Exchange in afternoon trade, up 3.17% from its previous close.